Global Export Compliance Guide For Microneedle Products: Cosmetic Or Medical Device?

1. Why Microneedle Compliance Is Critical in 2025

2025 marks a pivotal year of global regulatory tightening for microneedle (MN) products, including dissolving microneedle eye patches, acne patches, and microcrystal skin resurfacing products. All cross-border brands and manufacturers are facing a decisive compliance question: whether their products should be classified as cosmetics or medical devices.

The two categories differ drastically in compliance cost, timeline and market risk.

Cosmetic route: Registration takes only several weeks with a total compliance cost of a few thousand US dollars, enabling fast market launch and mass distribution.

Medical device route: Registration lasts for years with high expenditures ranging from tens to hundreds of thousands of US dollars. Complete clinical trial data and systematic qualification documents are mandatory.

If already-launched products are reclassified as medical devices by regulators, enterprises will face product removal, inventory ban, customs detention, store penalties, brand repositioning and full-channel adjustment, resulting in devastating business losses.

With the implementation of new global regulations in 2025, the long-existing grey area for microneedle cosmetics is disappearing rapidly. This article summarizes the latest regulatory policies of China, South Korea, Japan, Thailand and the United States, and provides practical solutions for product upgrading, marketing revision and market declaration.

2. Global Regulatory Comparison

3. In-depth Regulatory Interpretation by Market

3.1 China NMPA: Zero Tolerance for Skin Penetration

On June 17, 2025, NMPA officially clarified the classification of microneedle and microcrystal products. Any product named or claimed as "microneedle/microcrystal" that operates beyond skin surface application is excluded from cosmetic definition and shall be regulated as medical device or drug.

As early as December 2023, local market supervision authorities announced thatno legal microneedle cosmetics exist in the Chinese market. Multiple brands have been ordered to cancel filings and remove products due to illegal keyword usage.

China cosmetic compliance rules: Products must act only on the skin surface. All "microneedle, microcrystal" words must be deleted. Marketing wording is limited to "surface application, dissolving and absorption". Words such as piercing, penetrating and breaking skin are strictly forbidden.

3.2 South Korea MFDS: Strictest Advertising & Label Control

On January 21, 2025, MFDS issued new cosmetic advertisement regulations, explicitly banning "microneedle usage implication" as misleading promotion. The word "microneedle" and any skin-piercing hints are prohibited on product names, packages and marketing content.

A special inspection in August 2024 covered 100 microneedle products, among which 82 were confirmed with false promotion, including penetration hints, exaggerated anti-aging effects and implied medical endorsement, leading to the 2025 policy upgrade.

Qualified surface-care products can apply for functional cosmetic certification (whitening, anti-wrinkle) with wider claim ranges, requiring 4–6 months review, complete efficacy data and designated KLH agent.

3.3 Japan PMDA/MHLW: Flexible Case-by-Case Evaluation

Based on the PMD Act, Japan classifies products according to stratum corneum penetration and physiological impact. There is no unified needle length standard. Enterprises can apply for official PMDA pre-consultation during R&D to confirm product classification in advance.

Non-penetrating products qualify for cosmetic notification, while penetrating products require Class II–IV medical device registration. The Japanese term for microneedle is not absolutely prohibited, but any piercing implication will trigger medical device classification.

3.4 Thailand FDA: The Only Market with Definite Quantitative Standards

In November 2025, Thai FDA released three official drafts, setting a clear threshold: only dissolvable microneedle patches ≤100μm can be sold as cosmetics.

Products exceeding 100μm, adopting insoluble materials or claiming medical effects are forbidden from cosmetic registration. Approved products must carry six mandatory warning labels, with a 180-day transition period for stock products.

Scientific basis: Human stratum corneum thickness ranges from 15–50μm, and total epidermal thickness is below 100μm. The 100μm limit ensures no dermal layer or nerve contact, balancing efficacy and safety.

3.5 US FDA: 300μm Threshold with Strict Claim Restrictions

According to FDA's 2017 regulatory guideline, microneedle products ≤300μm acting only on the stratum corneum can be classified as cosmetics.

Notably, product claims override physical parameters. Even within 300μm, products claiming scar treatment, wound healing or skin structure modification will be classified as Class II medical devices.

4. Three-step Practical Compliance Solution

Step 1: Product Hardware Rectification

1. Control needle length according to target market standards (≤100μm for Thailand, ≤300μm for USA);

2. Adopt fully dissolvable materials;

3. Conduct in-vitro skin tests to verify no stratum corneum penetration;

4. Complete safety evaluation including skin irritation and sensitization tests.

Step 2: Branding, Packaging & Marketing Upgrade

1. Remove all "microneedle, microcrystal" keywords;

2. Reposition products as essence patches, infusion patches and lattice skincare patches;

3. Revise instructions to "surface application and active ingredient release";

4. Limit claims within cosmetic scope and reserve full efficacy evaluation documents.

Step 3: Market-specific Declaration Requirements